Takeda Pharmaceutical is foreseen to post a net loss for Q4. Retail investors, at 51%, are Takeda's biggest shareholders with institutional ownership at 48%. Operating profit for FY23 has declined, causing a slip in the stock value. However, with the rating upgraded to
Strong Buy, TAK is regarded as an attractive choice for value investors and a good pick for a high-yield dividend stock, yet there's a need for the net profits to grow. Recent dealings include the company being undervalued and the profitable licensing deal with
ImmunoGen. The full-year profit forecast has been sliced due to drug pipeline impairments. One of the most recent events to occur is Takeda's FDA approval for
Eohilia which may be a potential tailwind for the company. Concerns about the growth persist as the pipeline is expanding while rivalry with other companies impacts certain drug markets. Yet, TAK stock is considered to be fairly valued with potential upside. Takeda's dramatic M&A deal with
Shire has resulted in a loss forecast and a drop in share prices.
Takeda Pharmaceutical Stocks News Analytics from Mon, 09 Jan 2017 08:00:00 GMT to Fri, 10 May 2024 01:20:00 GMT -
Rating -3
- Innovation 3
- Information 4
- Rumor 0
